αααααβααΎαCYTK β’ NASDAQ
add
Cytokinetics, Inc.
39.15$
αααααααααα(0.38%)-0.15
39.00$
ααΆααα·αα 16 ααααΆ, 5:16:37 PM ααααβααα -4 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·αααΆαααΈααααΆααααΆααααααΆααα
α’αΆαααα·α
αα·αααΈαα»α
38.56$
α
αααααααααααα
37.79$ - 39.34$
α
ααααααα½αααααΆαα
α»αααααα
32.75$ - 69.90$
ααΎαβαα»αβααΈααααΆα
4.67Β αααΈααΆα USD
ααα ααα½αααΌαααααα
2.15Β ααΆα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
NASDAQ
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(USD) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 16.93Β ααΆα | 912.38% |
α
αααΆαααααα·ααααα·ααΆα | 62.34Β ααΆα | 41.31% |
α
αααΌααα»ααα | -150.02Β ααΆα | -9.59% |
ααααΆααα
αααααα»ααα | -886.28 | 89.18% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -1.26 | 8.70% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -136.66Β ααΆα | -12.86% |
α’ααααΆαααααααααΆαααααα·αααααΆα | β | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(USD) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 1.08Β αααΈααΆα | 75.01% |
ααααααααα»α | 1.40Β αααΈααΆα | 70.04% |
ααΆαααα½ααα»αααααΌαααα»α | 1.54Β αααΈααΆα | 26.96% |
ααΌαβααααα»α | -135.37Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 118.41Β ααΆα | β |
ααααααααααΉαααααα
| -33.53 | β |
ααα
ααααααΎαααααα | -24.50% | β |
ααα
ααααααΎααΎααα»α | -41.33% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(USD) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | -150.02Β ααΆα | -9.59% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -65.57Β ααΆα | 11.44% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | 110.86Β ααΆα | 236.18% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 2.38Β ααΆα | -98.59% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 47.97Β ααΆα | 259.80% |
ααα αΌαααΆα
αααααΆααααααα | -40.46Β ααΆα | 2.24% |
α’αααΈ
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
ααΆααααααΎαα‘αΎα
1997
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
498